Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman Sells 2,614 Shares

Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman sold 2,614 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $127.68, for a total value of $333,755.52. Following the completion of the sale, the director now directly owns 7,969 shares in the company, valued at approximately $1,017,481.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Natera Stock Up 2.5 %

NASDAQ:NTRA opened at $129.67 on Tuesday. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $132.01. The firm has a market capitalization of $15.92 billion, a PE ratio of -41.56 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock has a 50 day moving average of $112.73 and a 200-day moving average of $104.17.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter in the prior year, the firm earned ($0.97) EPS. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. Analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Morgan Stanley increased their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Robert W. Baird increased their target price on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Jefferies Financial Group assumed coverage on Natera in a research report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective on the stock. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $120.07.

Institutional Investors Weigh In On Natera

Several institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after buying an additional 60,127 shares during the last quarter. Thematics Asset Management boosted its position in Natera by 3.1% during the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after purchasing an additional 2,738 shares during the period. Crestline Management LP boosted its holdings in shares of Natera by 16.0% during the 4th quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after buying an additional 8,997 shares during the period. Russell Investments Group Ltd. grew its position in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after purchasing an additional 9,781 shares during the last quarter. Finally, International Assets Investment Management LLC grew its holdings in Natera by 6,007.5% in the 4th quarter. International Assets Investment Management LLC now owns 7,329 shares of the medical research company’s stock valued at $459,000 after buying an additional 7,209 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.